Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the Jefferies London Healthcare Conference in London, U.K., on Tuesday, November 19, 2024, at 3:30 a.m. ET/8:30 a.m. GMT.

A live webcast of the presentation will be available on the Nuvation Bio website at https://investors.nuvationbio.com/investors/. An archived recording will be available for 90 days following the event.

About Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel product candidates. Nuvation Bio’s portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-1511 (DDC), and NUV-868 (BET). Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, please visit www.nuvationbio.com and follow us on LinkedIn.

Nuvation Bio Investor Contact: ir@nuvationbio.com

Nuvation Bio Media Contact: media@nuvationbio.com

Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di Panacea Acquisition
Grafico Azioni Panacea Acquisition (NYSE:NUVB)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di Panacea Acquisition